Skip to main content
Clinical Trials/NCT06334549
NCT06334549
Recruiting
Phase 4

Effects of Vasopressor on Cerebral Oxygenation During General Anesthesia in Abdominal Surgery

Dalian Municipal Central Hospital1 site in 1 country180 target enrollmentMarch 5, 2024

Overview

Phase
Phase 4
Intervention
Ephedrine-P
Conditions
Hypotension Drug-Induced
Sponsor
Dalian Municipal Central Hospital
Enrollment
180
Locations
1
Primary Endpoint
Continual changes in Cerebral Oxygen Saturation
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to investigate whether norepinephrine(N), phenylephrine(P) or ephedrine(E) have different effect on cerebral oxygenation in abdominal surgery with propofol or sevoflurane.

Detailed Description

This study was a single-center, randomized, double-blinded, controlled trial. First, the effects of E, P, or N on cerebral oxygen saturation(rScO2) under general anesthesia in abdominal surgery were studied. Patients with abdominal surgery were evaluated using near-infrared spectroscopy. Continual changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR) will be measured with LiDCO rapidV3 monitoring system. To investigate the individualized therapeutic options \& specific mechanisms of the three vasopressors on rScO2 and CO.

Registry
clinicaltrials.gov
Start Date
March 5, 2024
End Date
December 5, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Dalian Municipal Central Hospital
Responsible Party
Principal Investigator
Principal Investigator

Liping Han

Professor & Vice Director

Dalian Municipal Central Hospital

Eligibility Criteria

Inclusion Criteria

  • ASA I-III, age 18-80 years
  • Elective abdominal surgery
  • Signed informed consent

Exclusion Criteria

  • Preoperative unstable blood hemodynamics
  • Allergy to ephedrine, phenylephrine or norepinephrine
  • Decrease in MAP \<20%
  • Severe cardiovascular disorder

Arms & Interventions

Ephedrine-Propofol

receive ephedrine 0.15mg/kg (configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Ephedrine-P

Phenylephrine-propofol

receive phenylephrine 2.5ug/kg(configured concentration 100ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Phenylephrine-P

Norepinephrine-propofol

receive norepinephrine 0.2ug/kg(configured concentration 8μg/ml) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Norepinephrine-P

Ephedrine-sevoflurane

receive Ephedrine 0.15mg/kg(configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Ephedrine-S

Phenylephrine-sevoflurane

receive phenylephrine 2.5ug/kg(configured concentration 80ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Phenylephrine-S

Norepinephrine-sevoflurane

receive norepinephrine 0.2ug/kg(configured concentration 8ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.

Intervention: Norepinephrine-S

Outcomes

Primary Outcomes

Continual changes in Cerebral Oxygen Saturation

Time Frame: 10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors

This outcome is measured by near-infrared spectroscopy

Secondary Outcomes

  • Continual changes in heart rate (HR)(10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors)
  • Continual changes in cardiac output (CO)(10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors)
  • Continual changes in stroke volume (SV)(10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors)
  • Continual changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP)(10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors)
  • Continual changes in systemic vascular resistance (SVR)(10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors)

Study Sites (1)

Loading locations...

Similar Trials